Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

2016 ESC Position Paper On Cancer Treatments And Cardiovascular Toxicity Developed Under The Auspices Of The ESC Committee For Practice Guidelines:  The Task Force For Cancer Treatments And Cardiovascular Toxicity Of The European Society Of Cardiology (ESC).

J. Zamorano, P. Lancellotti, Daniel Rodríguez Muñoz, V. Aboyans, R. Asteggiano, M. Galderisi, G. Habib, D. Lenihan, G. Lip, A. Lyon, T. López Fernández, D. Mohty, M. Piepoli, J. Tamargo, A. Torbicki, T. Suter
Published 2016 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
2-D : two-dimensional 3-D : three-dimensional 5-FU : 5-fluorouracil ACE : angiotensin-converting enzyme ARB : angiotensin II receptor blocker ASE : American Society of Echocardiography BNP : B-type natriuretic peptide CABG : coronary artery bypass graft CAD : coronary artery
This paper references
10.1016/j.thromres.2010.10.001
Arterial thrombosis in ambulatory cancer patients treated with chemotherapy.
M. Di Nisio (2011)
10.1118/1.2713216
Three-dimensional heart dose reconstruction to estimate normal tissue complication probability after breast irradiation using portal dosimetry.
R. Louwe (2007)
10.1002/clc.22106
Frequency of Severe Valvular Disease Caused by Mediastinal Radiation Among Patients Undergoing Valve Surgery in a Community‐Based, Regional Academic Medical Center
Kevin A. Copeland (2013)
10.1016/j.rec.2014.12.002
2014 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism
S. Konstantinides (2015)
American Society of Clinical Oncology 2008 clinical practice guideline update : use of chemotherapy and radiation ther
ML Hensley
Herceptin Adjuvant Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart (2005)
10.1016/j.ijcard.2012.10.079
Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study.
M. Lotrionte (2013)
10.1053/EUHJ.2000.2011
Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?
N. Bellenger (2000)
10.1371/journal.pone.0114445
Non-Vitamin K Antagonist Oral Anticoagulants and the Treatment of Venous Thromboembolism in Cancer Patients: A Semi Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes
T. Larsen (2014)
10.1200/JCO.2015.62.1797
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.
M. Piccart-Gebhart (2016)
10.1074/jbc.M308033200
Anthracyclines Induce Calpain-dependent Titin Proteolysis and Necrosis in Cardiomyocytes*
C. Lim (2004)
10.1016/S1470-2045(13)70335-8
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
D. Cameron (2013)
10.1186/1756-9966-32-88
Dosimetric and clinical advantages of deep inspiration breath-hold (DIBH) during radiotherapy of breast cancer
V. Bruzzaniti (2013)
10.2174/157340310791162668
Cardiac MRI in Infiltrative Disorders: A Concise Review
Neelima Penugonda (2010)
10.1200/JCO.2008.20.2267
Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer.
M. Tukenova (2010)
ESC CPG Position Paper Page 29 of 34 Position Paper 7 EJHF_654_9-42.indd
SL Soignet (2001)
10.1200/JCO.2014.56.7511
Exercise and risk of major cardiovascular events in adult survivors of childhood hodgkin lymphoma: a report from the childhood cancer survivor study.
L. Jones (2014)
10.1200/JCO.2004.06.033
Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.
O. Hequet (2004)
UNDERLYING CAUSES AND LONG-TERM SURVIVAL IN PATIENTS WITH INITIALLY UNEXPLAINED CARDIOMYOPATHY
M. G (2000)
TLC D-99 Study Group. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma
L Harris (2002)
2 - year follow - up of trastuzumab after adjuvant chemotherapy in HER 2 - positive breast cancer : a randomised controlled trial
I Smith (2007)
10.1200/JCO.1996.14.4.1333
BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases.
G. Doelken (1996)
10.1056/NEJMOA1411321
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Aspire Investigators (2015)
10.1200/JCO.2006.06.5391
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
S. Jones (2006)
10.1111/bcp.12149
Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis.
W. Qi (2013)
Cancer treatment and survivorship statistics
R Siegel (2012)
10.1093/eurheartj/ehs215
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.
P. Steg (2012)
10.1016/j.clcc.2011.03.021
An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition.
M. S. Copur (2011)
10.1200/JCO.2000.18.17.3078
Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.
B. Hutten (2000)
10.1016/J.IJROBP.2006.06.043
Effects of fractionated radiation on the brain vasculature in a murine model: blood-brain barrier permeability, astrocyte proliferation, and ultrastructural changes.
H. Yuan (2006)
10.1016/j.jacc.2015.04.059
Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next Level.
A. Barac (2015)
Cardiovascular toxicity of biologic agents for cancer therapy.
M. Bhave (2014)
10.1016/0002-9343(78)90802-1
Early anthracycline cardiotoxicity.
M. Bristow (1978)
Stent - ing versus surgery in patients with carotid stenosis after previous cervical radiation therapy : systematic review and meta - analysis
DM Gujral (2012)
10.1016/j.ygyno.2010.08.019
Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model.
K. Van Calsteren (2010)
10.1161/STROKEAHA.111.633743
Stenting Versus Surgery in Patients With Carotid Stenosis After Previous Cervical Radiation Therapy: Systematic Review and Meta-Analysis
M. Fokkema (2012)
10.1016/S1885-5857(09)60059-1
[ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012].
J. J. V. McMurray (2012)
10.1002/cncr.10201
Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma
L. Harris (2002)
10.1161/CIRCULATIONAHA.106.635144
Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition
D. Cardinale (2006)
10.1016/S0093-7754(01)90194-0
Pharmacokinetic profiles of doxorubicin in combination with taxanes.
F. Holmes (2001)
10.1016/j.ejca.2014.05.013
Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events.
M. Ewer (2014)
10.1200/JCO.2015.61.8413
Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial.
Pooja P. Advani (2016)
10.1016/S1470-2045(14)70409-7
Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.
S. Armenian (2015)
10.1016/S0046-8177(96)90447-5
Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases.
J. Veinot (1996)
10.1634/theoncologist.2008-0137
Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations.
M. Martín (2009)
10.1007/s40264-013-0047-5
Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval)
R. Shah (2013)
10.1016/j.ijcard.2013.03.133
Cardioncology: state of the heart.
M. C. Todaro (2013)
10.1111/j.1365-2125.2012.04417.x
Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta‐analysis of clinical trials
W. Qi (2013)
10.1016/j.radonc.2011.06.016
Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden.
P. Mcgale (2011)
10.1007/s11523-009-0112-2
Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?
E. Azambuja (2009)
10.1016/0002-9343(81)90574-X
Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart.
F. Brosius (1981)
10.1016/j.jacc.2013.10.061
Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab.
B. Ky (2014)
10.1200/JCO.2009.22.3271
Assessing risk of venous thromboembolism in the patient with cancer.
A. Khorana (2009)
10.1093/ehjci/jev024
EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry)--EURObservational Research Program of the European Society of Cardiology.
P. Lancellotti (2015)
10.1016/J.JMV.2013.09.003
Thromboses itératives de pontages artériels et cancer : à propos de trois cas
B. Villemur (2014)
10.1086/677359
Imatinib in Pulmonary Arterial Hypertension: C-Kit Inhibition
Samar Farha (2014)
10.1038/nrcardio.2015.65
Cardiotoxicity of anticancer treatments
M. Ewer (2015)
10.1161/01.HYP.0000239816.13007.c9
Effect of Regular Phosphodiesterase Type 5 Inhibition in Hypertension
J. Oliver (2006)
10.1056/NEJMSA060185
Chronic Health Conditions in Adult Survivors of Childhood Cancer
K. Oeffinger (2006)
10.1016/j.pcad.2010.04.002
Role of biomarkers in chemotherapy-induced cardiotoxicity.
D. Cardinale (2010)
10.1183/13993003.01032-2015
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Nazzareno Galiè (2015)
10.1002/14651858.CD008465.pub2
Exercise interventions on health-related quality of life for people with cancer during active treatment.
S. Mishra (2012)
10.1016/j.radonc.2014.11.018
The UK HeartSpare Study (Stage IB): randomised comparison of a voluntary breath-hold technique and prone radiotherapy after breast conserving surgery.
F. R. Bartlett (2015)
Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012;125:2128–2137
D Montani (2012)
10.1016/S0360-3016(96)00484-1
Selective tumor irradiation by infusional brachytherapy in nonresectable pancreatic cancer: a phase I study.
S. Order (1996)
10.1016/j.amjmed.2013.09.015
Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer.
M. Carrier (2014)
10.1016/j.ejca.2015.08.011
Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.
E. de Azambuja (2015)
10.1634/theoncologist.2012-0466
Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors.
D. Lenihan (2013)
10.1200/JCO.2005.08.789
Cardiotoxicity of cancer therapy.
Justin D. Floyd (2005)
10.1093/ehjci/jeu192
Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.
J. Plana (2014)
10.1002/ejhf.196
Protective effects of spironolactone against anthracycline‐induced cardiomyopathy
M. Akpek (2015)
10.1038/nrcardio.2015.139
Acute coronary syndromes: Bivalirudin versus heparin for ACS
K. Huynh (2015)
ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of
G Mancia (2013)
10.1002/ijc.1295
Use of paclitaxel in patients with pre‐existing cardiomyopathy: A review of our experience
A. Gollerkeri (2001)
10.2217/fca.15.55
Cardio-oncology: a new discipline in medicine to lead us into truly integrative care.
E. Clarke (2015)
10.1200/JCO.2009.23.2801
Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes.
K. Van Calsteren (2010)
10.1093/jnci/djv008
Risk for Valvular Heart Disease After Treatment for Hodgkin Lymphoma
D. Cutter (2015)
10.1016/S0140-6736(13)61094-6
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
A. Goldhirsch (2013)
10.1016/j.jacc.2013.05.019
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
C. Yancy (2013)
10.1038/ajh.2010.25
Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis.
V. Ranpura (2010)
10.1093/JNCI/DJM086
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
F. Scappaticci (2007)
10.1161/CIRCHEARTFAILURE.112.000055
Cardioprotective Effect of &bgr;-Adrenoceptor Blockade in Patients With Breast Cancer Undergoing Chemotherapy: Follow-Up Study of Heart Failure
S. Seicean (2013)
10.1016/j.jacc.2015.04.013
Comprehensive Echocardiographic Detection of Treatment-Related Cardiac Dysfunction in Adult Survivors of Childhood Cancer: Results From the St. Jude Lifetime Cohort Study.
G. Armstrong (2015)
10.1200/JCO.2007.14.8742
Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?
M. Ewer (2008)
10.1517/14740330902733961
Fluoropyrimidine-associated cardiotoxicity: revisited
M. W. Saif (2009)
Cardiac toxicity in
DJ Lenihan
10.1002/cncr.22965
Prospective assessment of radiotherapy‐associated cardiac toxicity in breast cancer patients: Analysis of data 3 to 6 years after treatment
R. Prosnitz (2007)
10.1200/JCO.2008.17.2627
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
M. Hensley (2009)
10.1200/JCO.2007.14.1242
Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma.
D. Hershman (2008)
10.1016/j.jacc.2012.09.035
Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy.
P. Thavendiranathan (2013)
10.1118/1.4757616
Dosimetric investigation of accelerated partial breast irradiation (APBI) using CyberKnife.
Q. Xu (2012)
10.1007/s00520-012-1413-z
Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial
M. Barginear (2012)
10.1007/BF01728765
Detection of radiation-induced myocardial damage by technetium-99m sestamibi scintigraphy
G. Gyenes (2005)
10.1016/j.cardfail.2013.12.018
Cancer therapy-induced left ventricular dysfunction: interventions and prognosis.
Akanksha Thakur (2014)
10.1016/S0002-9343(88)80268-7
Prophylaxis of 5-fluorouracil-induced coronary vasospasm with calcium channel blockers.
L. Oleksowicz (1988)
10.1038/nrc2106
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
T. Force (2007)
10.1016/j.jacc.2014.06.1167
Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
P. Vejpongsa (2014)
10.1016/j.jacc.2015.07.033
Burgeoning Cardio-Oncology Programs: Challenges and Opportunities for Early Career Cardiologists/Faculty Directors.
T. Okwuosa (2015)
10.1016/j.jmv.2013.09.003
[Arterial bypass iterative thrombosis and cancer: three cases].
B. Villemur (2014)
10.1007/s00228-013-1598-1
Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis
Z. Wang (2013)
10.1016/j.jacc.2013.11.026
Insights into onco-cardiology: atrial fibrillation in cancer.
D. Farmakis (2014)
10.1093/JNCI/DJK064
Long-term risk of cardiovascular disease in 10-year survivors of breast cancer.
M. Hooning (2007)
10.1200/JCO.2014.60.1799
Update on metastatic gastric and esophageal cancers.
M. Shah (2015)
10.1016/j.pcad.2010.05.006
Cardiac toxicity from systemic cancer therapy: a comprehensive review.
G. Curigliano (2010)
10.1016/S1470-2045(08)70003-2
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.
S. Wu (2008)
10.1016/j.jacc.2010.07.023
Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?
Geoffrey J. Yoon (2010)
Adjuvant Trastuzumab in HER 2-Positive Breast Cancer
D. Slamon (2011)
10.1016/0958-3947(91)90089-K
Estimation of doses to heart, coronary arteries, and spinal cord in mediastinal irradiation for Hodgkin's disease.
S. Vijayakumar (1991)
10.1161/STROKEAHA.111.615203
Ischemic Stroke and Transient Ischemic Attack After Head and Neck Radiotherapy: A Review
C. Plummer (2011)
10.1016/j.echo.2009.08.006
Radiotherapy-induced mitral stenosis: a three-dimensional perspective.
M. Malanca (2010)
10.1161/CIRCULATIONAHA.112.000765
Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study
M. Hoeper (2013)
10.1016/j.jacc.2014.11.036
Screening for cardiac autonomic dysfunction among Hodgkin lymphoma survivors treated with thoracic radiation.
K. Ness (2015)
Questions and answers on the review of dexrazoxane - containing medicines , powder for solution for infusion , 500 mg
N Kalay
Comparative pathology: radiation-induced coronary artery disease in man and animals.
R. Virmani (1998)
10.1200/JCO.2008.20.5013
Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase II
J. Sparano (2009)
10.1016/j.ijcard.2010.03.003
Cardiac side-effects of cancer chemotherapy.
Jean-Jacques Monsuez (2010)
10.1200/JCO.1991.9.7.1215
Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens.
A. Braverman (1991)
10.1200/JCO.2006.09.6925
Molecularly targeted oncology therapeutics and prolongation of the QT interval.
E. Strevel (2007)
10.1007/s00432-007-0250-9
Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study
C. Kosmas (2007)
10.1016/S0735-1097(00)00748-8
Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy.
D. Cardinale (2000)
10.1016/S1470-2045(14)70420-6
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
H. Wilke (2014)
10.1714/1234.13659
[Guidelines on the management of valvular heart disease (version 2012). The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)].
A. Vahanian (2013)
10.1118/1.3666946
Prior image constrained compressed sensing: implementation and performance evaluation.
P. T. Lauzier (2012)
10.1093/jnci/djs317
Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study
E. Bowles (2012)
10.1016/j.jacc.2013.02.072
Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of
X. Bosch (2013)
10.1200/JCO.2009.27.3615
Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.
D. Cardinale (2010)
10.2165/00002018-200831060-00002
Cardiotoxicity Profile of Trastuzumab
S. Ewer (2008)
10.1002/cncr.24219
A woman's heart
M. Ewer (2009)
Coronary artery dosimetry in intact left breast irradiation.
M. R. Storey (2001)
10.1053/J.SEMINONCOL.2005.03.013
Cardiac toxicity following thoracic radiation.
R. Prosnitz (2005)
10.1016/j.jsams.2009.03.002
Australian Association for Exercise and Sport Science position stand: optimising cancer outcomes through exercise.
S. Hayes (2009)
10.1136/hrt.69.6.496
Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment.
F. Orzan (1993)
10.1097/EDE.0b013e3182300720
Hypertension and Risk of Renal Cell Carcinoma Among White and Black Americans
J. Colt (2011)
10.1016/j.ajpath.2014.10.021
Chemotherapy-induced pulmonary hypertension: role of alkylating agents.
Benoît Ranchoux (2015)
10.1200/JCO.2003.04.173
Cardiovascular disease as a long-term complication of treatment for testicular cancer.
R. Huddart (2003)
10.1001/jamainternmed.2015.1180
Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk.
Frederika A. van Nimwegen (2015)
10.1056/NEJM200103153441101
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
10.1016/j.jacc.2013.01.090
Cardiac complications of thoracic irradiation.
C. Jaworski (2013)
10.1002/14651858.CD006468.pub5
Anticoagulation for people with cancer and central venous catheters.
E. Akl (2014)
Trastuzumab therapy in Australia : which patients with HER 2 + metastatic
CY Lu
10.1016/S1470-2045(13)70093-7
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
R. Motzer (2013)
10.1001/jama.2013.1363
Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy.
A. Gulati (2013)
10.1038/nrcardio.2010.121
Cardiotoxicity of anticancer treatments: what the cardiologist needs to know
M. Ewer (2010)
10.1016/j.ijcard.2008.03.036
Appraising cardiotoxicity associated with liposomal doxorubicin by means of tissue Doppler echocardiography end-points: rationale and design of the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study.
M. Lotrionte (2009)
10.1038/jhh.2013.30
Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis
T. Funakoshi (2013)
10.1097/PPO.0b013e3181ce46f9
Breast Cancer During Pregnancy: Maternal and Fetal Outcomes
E. Cardonick (2010)
10.1093/ehjci/jet159
Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection.
K. Negishi (2014)
10.1007/s12012-012-9164-0
Cardiac Toxicity of Targeted Therapies Used in the Treatment for Solid Tumours: A Review
M. Svoboda (2012)
10.1016/S0140-6736(14)60845-X
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
E. Garon (2014)
10.1093/eurheartj/ehu278
2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Ca
S. Windecker (2014)
Natriuretic peptide-based 2795 ESC CPG Position Paper 112bis
M Ledwidge (2017)
10.1016/j.accreview.2004.02.013
Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy.
Matthew C. Hull (2003)
10.1200/JCO.2014.56.1373
Individual prediction of heart failure among childhood cancer survivors.
E. Chow (2015)
10.1200/JCO.2013.53.9288
Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).
E. de Azambuja (2014)
10.1093/eurheartj/ehs109
Guidelines on the management of valvular heart disease (version 2012).
A. Vahanian (2012)
10.1001/jama.2013.7588
Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial.
M. Ledwidge (2013)
Natriuretic peptide-based ESC CPG Position Paper Page 28 of 34 36 ESC iti EJHF_654_9-42.indd 36 09/12/16 8:59 PM screening and collaborative care for heart failure: the STOP-HF randomized trial
M Ledwidge (2013)
10.1161/HYPERTENSIONAHA.109.129973
Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression
Carie S. Facemire (2009)
10.1001/JAMA.289.16.2120
What clinicians should know about the QT interval.
S. Al-Khatib (2003)
10.1200/JCO.2006.08.6595
Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer.
C. Correa (2007)
10.1161/01.CIR.0000130926.51766.CC
Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy
D. Cardinale (2004)
10.1016/j.jchf.2012.09.001
The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients.
P. S. Hall (2013)
10.1016/j.echo.2013.02.008
Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity.
K. Negishi (2013)
10.1093/eurheartj/ehs181
Cancer drugs and the heart: importance and management.
T. Suter (2013)
10.1200/JCO.2015.62.4718
Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.
J. Moslehi (2015)
10.1016/j.clon.2013.10.002
Clinical features of radiation-induced carotid atherosclerosis.
D. Gujral (2014)
10.1161/CIR.0b013e3182a88099
Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions A Scientific Statement From the American Heart Association
S. Lipshultz (2013)
10.1111/jth.12070
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
D. Farge (2013)
10.1001/JAMA.1991.03470120074036
Cardiac toxicity 4 to 20 years after completing anthracycline therapy.
L. Steinherz (1991)
10.1200/JCO.2012.46.6086
Endothelial damage in long-term survivors of childhood cancer.
C. Brouwer (2013)
10.1016/j.ijcard.2012.06.023
Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study.
M. Kaya (2013)
10.1093/ejcts/ezu366
2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous
P. Kolh (2014)
10.1093/eurheartj/ehv318
2015 ESC Guidelines for the diagnosis and management of pericardial diseases
Y. Adler (2015)
10.1053/j.seminoncol.2014.04.005
Therapy for cancer-related thromboembolism.
C. Frère (2014)
10.1002/14651858.cd003917.pub2
Cardioprotective interventions for cancer patients receiving anthracyclines.
E. C. van Dalen (2005)
10.1200/JCO.1995.13.11.2688
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
L. Gianni (1995)
10.1200/JCO.2014.59.7351
Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014.
G. Lyman (2015)
10.7326/0003-4819-94-4-430
Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography.
J. Gottdiener (1981)
10.1016/0002-9149(87)90345-6
Clinical and angiographic features of coronary artery disease after chest irradiation.
P. Mceniery (1987)
10.1200/JCO.2007.12.2481
Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane.
E. Barry (2008)
10.1056/NEJMc1215887
ERBB2 inhibition and heart failure.
G. Cote (2013)
10.1016/J.REC.2011.11.007
ESC Guidelines on the Diagnosis and Treatment of Peripheral Artery Diseases
M. Tendera (2012)
10.1017/S1047951115000906
Cardiac complications in childhood cancer survivors treated with anthracyclines.
V. Franco (2015)
10.1200/JCO.2012.43.0702
Increased tricuspid regurgitant jet velocity by Doppler echocardiography in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study.
G. Armstrong (2013)
10.1016/J.REPCE.2013.10.001
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
J. McMurray (2013)
10.1093/EURHEARTJ/EHL428
Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology.
A. Vahanian (2007)
10.1161/CIRCULATIONAHA.111.079921
Pulmonary Arterial Hypertension in Patients Treated by Dasatinib
D. Montani (2012)
10.1182/blood-2014-09-594432
Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.
P. Valent (2015)
10.1111/bcp.12387
Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta‐analysis of 36 clinical trials
W. Qi (2014)
10.1093/eurheartj/ehw022
Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol
Geeta Gulati (2016)
10.1056/NEJMoa1303989
Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
R. Motzer (2013)
10.1093/annonc/mdn713
Management of hypertension in angiogenesis inhibitor-treated patients.
H. Izzedine (2009)
10.1200/JCO.2006.09.1611
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
T. Suter (2007)
10.1182/BLOOD-2006-07-034405
Late cardiotoxicity after treatment for Hodgkin lymphoma.
B. Aleman (2007)
10.1007/s12350-013-9707-1
Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively
R. Schwartz (2013)
10.1016/j.ctrv.2010.11.001
Cardiovascular effects of systemic cancer treatment.
E. Senkus (2011)
10.1023/A:1008365716693
Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.
T. Safra (2000)
10.1016/j.jjcc.2009.03.009
Sorafenib-induced acute myocardial infarction due to coronary artery spasm.
Y. Arima (2009)
10.1200/JCO.2005.05.827
Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.
M. Ewer (2005)
10.1161/CIRCULATIONAHA.111.021774
Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms.
J. Scott (2011)
10.1093/annonc/mdr348
Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors.
C. Serrano (2012)
10.1016/j.cjca.2014.04.029
Chemotherapy-induced cardiotoxicity: detection, prevention, and management.
J. Truong (2014)
10.1093/ANNONC/MDH097
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
M. O'Brien (2004)
10.1093/eurheartj/ehr347
Characteristics and long-term outcome of non-immune isolated atrioventricular block diagnosed in utero or early childhood: a multicentre study.
Alban-Elouen Baruteau (2012)
10.1016/S0360-3016(96)00295-7
Symptomatic coronary artery disease after mantle irradiation for Hodgkin's disease.
V. King (1996)
10.1002/pd.3847
Effects of chemotherapy during pregnancy on the maternal and fetal heart
M. M. Gziri (2012)
10.1056/NEJMc1310231
Radium-223 in prostate cancer.
H. Biersack (2013)
10.1038/sj.bjc.6604909
Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring
A. Jones (2009)
10.1093/eurjhf/hfq213
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology
T. Eschenhagen (2011)
10.1067/MNC.2003.7
Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era
I. Mitani (2003)
10.1016/j.jcmg.2012.11.017
Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.
Brandon C. Drafts (2013)
10.1200/JCO.2015.60.8851
Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404.
B. Asselin (2016)
10.1016/0002-9149(83)90209-6
Cardiac disease after radiation therapy for Hodgkin's disease: analysis of 48 patients.
M. M. Applefeld (1983)
10.1093/ANNONC/MDJ134
Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy.
M. Marty (2006)
10.1200/JCO.1996.14.12.3112
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
M. Venturini (1996)
10.1111/jcpt.12124
Incidence and risk‐factors of CHOP/R‐CHOP‐related cardiotoxicity in patients with aggressive non‐Hodgkin's lymphoma
S. Limat (2014)
VEGF inhibition and renal thrombotic microangiopathy.
D. Nochy (2008)
10.1016/j.hfc.2011.03.002
Biomarker approach to the detection and cardioprotective strategies during anthracycline chemotherapy.
B. Ky (2011)
10.1016/j.jacc.2009.02.050
Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management.
E. T. Yeh (2009)
10.1093/annonc/mdr294
Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.
D. Lenihan (2012)
10.1016/j.ctrv.2013.03.005
Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors.
A. Polk (2013)
Questions and answers on the review of dexrazoxane - containing medicines , powder for solution for infusion , 500 mg . Outcome of a procedure under Article 31 of Directive 2001 / 83 / EC as amended
N Kalay
10.1160/TH13-02-0131
High incidence of venous thromboembolism despite electronic alerts for thromboprophylaxis in hospitalised cancer patients.
R. Lecumberri (2013)
10.1016/j.breast.2013.04.011
Trastuzumab therapy in Australia: which patients with HER2+ metastatic breast cancer are assessed for cardiac function?
C. Lu (2013)
10.1093/jnci/djp147
Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma.
M. D. De Bruin (2009)
10.1056/NEJMoa0910383
Adjuvant trastuzumab in HER2-positive breast cancer.
D. Slamon (2011)
10.1016/j.jacc.2009.03.095
Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.
D. Cardinale (2010)
10.1016/j.jacc.2014.01.073
Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review.
P. Thavendiranathan (2014)
10.1016/S0958-3947(00)00047-9
The effect of constipation on rectal dosimetry following prostate brachytherapy.
G. Merrick (2000)
10.1056/NEJMOA052306
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
M. Piccart-Gebhart (2005)
10.1158/1078-0432.CCR-06-1017
Challenges of Evaluating the Cardiac Effects of Anticancer Agents
S. Bates (2006)
10.1126/scitranslmed.3006490
Cardio-Oncology: It Takes Two to Translate
J. Moslehi (2013)
10.1093/ANNONC/MDF035
Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil.
N. Frickhofen (2002)
10.1186/2162-3619-1-10
Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis
S. Rafiyath (2012)
ESC Guidelines on the diagnosis and management of acute pulmonary embolism
A. Torbicki (2014)
10.1093/eurheartj/eht151
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
G. Mancia (2013)
Cardiovascular disease in adult life after childhood cancer in Scandinavia : a population - based cohort study of 32 , 308 one - year survivors
M Aapro (2015)
10.1002/ccd.21681
Radiation‐induced peripheral artery disease
J. Jurado (2008)
10.1200/JCO.2012.46.6854
American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care.
M. McCabe (2013)
10.1161/CIRCIMAGING.113.000899
Cardiac MRI in the Assessment of Cardiac Injury and Toxicity From Cancer Chemotherapy: A Systematic Review
P. Thavendiranathan (2013)
10.1016/j.pcad.2010.06.002
The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society.
D. Lenihan (2010)
10.3109/08880018.2010.503335
COMPARISON OF DOXORUBICIN CARDIOTOXICITY IN PEDIATRIC SARCOMA PATIENTS WHEN GIVEN WITH DEXRAZOXANE VERSUS AS CONTINUOUS INFUSION
W. Huh (2010)
10.1038/nm.2919
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Sui Zhang (2012)
10.1093/annonc/mdq609
Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.
M. Aapro (2011)
10.1002/14651858.CD005006.pub4
Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
E. C. van Dalen (2010)
Anthracycline cardiotoxicity: clinical aspects, recognition, monitoring, treatment, and prevention
MS Ewer (2013)
10.1016/j.ijrobp.2009.12.054
Cardiac magnetic resonance imaging findings in 20-year survivors of mediastinal radiotherapy for Hodgkin's disease.
W. Machann (2011)
10.5603/KP.2015.0242
[2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension].
N. Galié (2015)
10.1002/ijc.28334
Arterial hypertension and cancer
A. Milan (2014)
10.1118/1.1898463
Accounting for beta-particle energy loss to cortical bone via paired-image radiation transport (PIRT).
A. Shah (2005)
10.1093/ehjci/jet123
Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography.
P. Lancellotti (2013)
10.1016/S1470-2045(09)70095-6
Experts call for urgent skin-cancer awareness campaigns in Chile.
G. Kenyon (2009)
10.1001/JAMA.1993.03510160067031
Factors affecting late mortality from heart disease after treatment of Hodgkin's disease.
S. Hancock (1993)
10.6004/JNCCN.2011.0064
Risk assessment and prophylaxis for VTE in cancer patients.
A. Khorana (2011)
10.2147/TCRM.S49063
New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients
G. Gerotziafas (2014)
10.1016/j.pcad.2010.06.007
Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?
D. Sawyer (2010)
10.1158/1078-0432.CCR-09-0628
Adjuvant Trastuzumab Induces Ventricular Remodeling Despite Aerobic Exercise Training
M. Haykowsky (2009)
10.7326/0003-4819-126-10-199705150-00020
Anthracycline-induced cardiotoxicity.
K. Shan (1996)
10.1002/cncr.21478
Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone
H. Nakamae (2005)
10.7326/0003-4819-96-2-133
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.
S. Legha (1982)
10.1186/2050-6511-15-47
A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity
A. Polk (2014)
10.1200/JCO.2006.10.4976
Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
M. Pinder (2007)
10.1200/JCO.2008.21.1953
Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings.
L. Diller (2009)
10.1016/j.ejca.2012.12.027
Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.
J. Ferlay (2013)
10.1111/j.1600-0412.2012.01524.x
Chemotherapy during pregnancy: effect of anthracyclines on fetal and maternal cardiac function
M. M. Gziri (2012)
10.1093/ehjci/jev014
Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.
R. Lang (2015)
10.1016/J.BREASTDIS.2013.07.034
Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
M. Zibelman (2013)
10.1200/JCO.2012.43.3755
Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.
J. Hainsworth (2013)
10.1093/eurheartj/ehu283
2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.
S. Konstantinides (2014)
10.1016/j.critrevonc.2014.12.008
Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
P. Ghatalia (2015)
10.1016/j.echo.2014.11.003
Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging.
J. Voigt (2015)
10.3322/caac.21149
Cancer treatment and survivorship statistics, 2012
R. Siegel (2012)
10.1056/NEJMOA035153
The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
S. Lipshultz (2004)
10.1093/jnci/djn206
New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
M. Ryberg (2008)
10.1016/S1470-2045(09)70232-3
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.
G. Agnelli (2009)
10.1056/NEJMp1313140
Cancer-drug discovery and cardiovascular surveillance.
J. Groarke (2013)
10.1007/s40264-014-0258-4
Cancer Chemotherapy and Cardiac Arrhythmias: A Review
J. Tamargo (2015)
10.1200/JCO.1997.15.4.1318
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
S. Swain (1997)
10.1016/j.ahj.2011.10.018
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
Richard M. Steingart (2012)
10.1200/JCO.1997.15.4.1333
Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.
S. Swain (1997)
10.6004/JNCCN.2014.0155
Approach to the management of incidental venous thromboembolic events in patients with cancer.
C. O'Connell (2014)
Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase.
J. Doroshow (1983)
10.1016/S0140-6736(07)60028-2
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
I. Smith (2007)
10.1200/JCO.2013.49.3205
Modifiable risk factors and major cardiac events among adult survivors of childhood cancer.
G. Armstrong (2013)
10.1056/NEJMoa1411321
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
A. Stewart (2015)
Vitamin b12 and folate deficiency: prevalence, clinical correlates and outcome in chronic heart failure
V. D. H. Wal (2014)
10.1097/HJH.0B013E3281FC975A
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
G. Mancia (2007)
10.1016/0049-3848(82)90302-4
Determination of α2-plasmin inhibitor in body fluids
O. Matsuo (1982)
10.1002/pd.2752
Uterine torsion in a monochorionic diamniotic (MCDA) twins pregnancy
E. Zhang (2011)
10.3109/02841869009091790
Failure of preventing 5-fluorouracil cardiotoxicity by prophylactic treatment with verapamil.
J. Eskilsson (1990)
10.1093/ANNONC/MDS293
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines.
G. Curigliano (2012)
10.7326/0003-4819-99-6-745
Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy.
F. Torti (1983)
10.1517/14740338.2015.1010505
Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma
E. Boyle (2015)
10.1093/jnci/djp440
Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention
A. Albini (2010)
10.1016/J.JACC.2006.07.052
Protective effects of carvedilol against anthracycline-induced cardiomyopathy.
N. Kalay (2006)
10.1016/J.THROMRES.2005.10.015
Chemotherapy-induced thrombosis.
T. Haddad (2006)
10.1160/TH14-11-0977
Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer.
S. Schulman (2015)
10.1016/S0140-6736(13)61719-5
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
C. Fuchs (2014)
Chronic damage to medium and large arteries following irradiation.
E. Louis (1974)
10.1016/J.BREASTDIS.2015.10.010
Prevalence of Cerebral Small-Vessel Disease in Long-Term Breast Cancer Survivors Exposed to Both Adjuvant Radiotherapy and Chemotherapy
S. Kesler (2015)
10.5603/KP.2015.0190
[2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death].
S. Priori (2015)
10.1161/CIRCULATIONAHA.108.776831
Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics
M. Chen (2008)
10.1016/j.ijrobp.2009.04.093
Radiation dose-volume effects in the heart.
G. Gagliardi (2010)
10.1016/J.EHJ.2004.02.002
Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology.
B. Maisch (2004)
10.1093/eurheartj/ehn310
Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC).
A. Torbicki (2008)
10.1016/S0140-6736(05)66544-0
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
Early Breast Cancer Trialists' Collaborative Group (2005)
10.1093/eurheartj/eht296
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.
G. Montalescot (2013)
10.1016/S0140-6736(05)66544-0
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
O. Abe (2005)
10.1001/ARCHINTE.1981.00340060066015
Cardiotoxicity associated with high-dose cyclophosphamide therapy.
J. Gottdiener (1981)
10.1093/eurheartj/ehv320
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).
M. Roffi (2016)
10.1056/NEJMoa1209825
Risk of ischemic heart disease in women after radiotherapy for breast cancer.
S. Darby (2013)
10.1200/JCO.2009.27.2757
Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
T. Choueiri (2010)
10.1200/JCO.2011.40.3584
Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging.
G. Armstrong (2012)
10.1016/S0735-1097(03)00759-9
Asymptomatic cardiac disease following mediastinal irradiation.
P. Heidenreich (2003)
10.1159/000091638
Pulmonary Arterial Hypertension after Childhood Cancer Therapy and Bone Marrow Transplantation
A. Limsuwan (2006)
10.1016/S1470-2045(12)70525-9
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
J. Mackey (2013)
10.1093/jnci/djq091
Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors
M. Maitland (2010)
10.1159/000093551
Mechanisms of Cancer-Induced Thrombosis in Cancer
F. Rickles (2006)
10.1161/JAHA.113.000472
Risk Prediction Model for Heart Failure and Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer
Ghideon Ezaz (2014)
10.1161/CIRCULATIONAHA.114.013777
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
D. Cardinale (2015)
10.1093/jnci/dju232
Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities.
N. Shelburne (2014)
10.1056/NEJMOA052122
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
E. H. Romond (2005)
10.1200/JCO.1992.10.1.117
ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.
J. Speyer (1992)
Ischemic
C Plummer
10.1016/S1470-2045(09)70287-6
The metabolic syndrome in cancer survivors.
E. C. de Haas (2010)
10.1182/BLOOD.V126.23.4250.4250
Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866)
S. Russell (2015)
10.7326/0003-4819-91-5-710
Risk factors for doxorubicin-induced congestive heart failure.
D. V. Von Hoff (1979)
10.1016/S0002-9149(03)00546-0
Echocardiographic features of radiation-associated valvular disease.
D. Hering (2003)
Venous thromboembolism prophylaxis and treatment in patients with cancer.
A. Kakkar (2008)
10.1016/J.EJCA.2007.01.018
Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005.
J. Verweij (2007)
10.1186/1477-9560-11-21
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies
M. Prins (2013)
10.1007/s10549-014-3253-7
Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer
A. Yu (2014)
10.1080/07347332.2014.955243
Correlates of Positive Health Behaviors in Cancer Survivors: Results from the 2010 LIVESTRONG Survey
C. Low (2014)
10.1200/JCO.2011.35.5669
High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis.
R. A. Moore (2011)
10.1161/CIRCULATIONAHA.112.100560
Cancer Therapy–Induced Cardiac Toxicity in Early Breast Cancer: Addressing the Unresolved Issues
Michel G. Khouri (2012)
10.1093/annonc/mdu055
Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk.
C. Lestuzzi (2014)
10.1080/02841860802314720
Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis
X. Zhu (2009)
10.1200/JCO.2005.02.3879
Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
C. Tebbi (2007)
10.1016/j.mayocp.2014.05.013
Evaluation and management of patients with heart disease and cancer: cardio-oncology.
J. Herrmann (2014)
10.1093/eurheartj/eht114
Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease.
J. Groarke (2014)
10.4065/83.6.679
Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials.
E. Perez (2008)
10.1161/CIRCIMAGING.112.973321
Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab
Heloisa Sawaya (2012)
10.1002/14651858.CD006650.pub2
Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer.
E. Akl (2008)
10.1002/ijc.29468
Cardiovascular disease in Adult Life after Childhood Cancer in Scandinavia: A population‐based cohort study of 32,308 one‐year survivors
T. Gudmundsdottir (2015)
10.1016/S0140-6736(04)17662-9
Repeat sudden unexpected and unexplained infant deaths: natural or unnatural?
RG Carpenter (2005)
10.1200/JCO.2013.51.8480
Burnout and career satisfaction among US oncologists.
T. Shanafelt (2014)
10.1016/j.ijrobp.2009.02.091
Radiation dose-volume effects in the brain.
Y. Lawrence (2010)
10.1016/0360-3016(94)00656-6
Radiation injury to the heart.
J. Stewart (1995)
10.4324/9780429266003-2
Survivors
Gwyn McClelland (1891)
Pharmacovigilance Study Team. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study
E J Bowles (2012)
10.1016/0167-8140(94)90008-6
Cardiac lesions after mediastinal irradiation for Hodgkin's disease.
C. Glanzmann (1994)
10.1200/JCO.2010.29.9362
Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study.
H. S. Haugnes (2010)
10.1200/JCO.2014.58.7782
Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
I. Krop (2015)
10.1056/NEJMra1106180
Proteotoxicity and cardiac dysfunction--Alzheimer's disease of the heart?
M. Willis (2013)
10.1080/02841860510007440
The pathology of ionizing radiation as defined by morphologic patterns*
L. Fajardo (2005)
10.1124/jpet.106.103846
Paclitaxel and Docetaxel Stimulation of Doxorubicinol Formation in the Human Heart: Implications for Cardiotoxicity of Doxorubicin-Taxane Chemotherapies
E. Salvatorelli (2006)
10.1002/cncr.11407
Congestive heart failure in patients treated with doxorubicin
S. Swain (2003)
10.1200/JCO.2012.45.2938
Late cardiac effects of cancer treatment.
D. Lenihan (2012)
10.1016/j.jacc.2012.07.067
Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study.
S. Seicean (2012)
10.1002/cncr.28061
Cardiac toxicity in cancer survivors
D. Lenihan (2013)
10.1002/14651858.CD006243.pub2
Trastuzumab containing regimens for early breast cancer.
L. Moja (2012)
Pharmacovigilance Study Team. Risk of heart 2793 ESC CPG Position Paper by gest on Jauary 20
EJ Bowles (2017)
10.1200/JCO.2016.66.7840
Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma.
R. Mazzola (2016)
10.1200/JCO.2001.19.18.3852
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.
S. Soignet (2001)
http://eurhexfordjournals.org/ D ow nladed from Ellison R, Warrell RP Jr. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia
SL Soignet (2017)
Pacemaker-implantation prevents sudden death in a large family with LQT3
M. V. D. Berg (1999)
10.1200/JCO.2007.25.18_SUPPL.1106
Cardiac safety of pegylated liposomal doxorubicin (PLD) in combination with trastuzumab (T) in patients with metastatic breast cancer (MBC): Results from a multicenter phase II study
E. Stickeler (2007)
10.1182/BLOOD.V126.23.4257.4257
Biomarkers of Cardiotoxicity Among Multiple Myeloma Patients Subsequently Treated with Proteasome Inhibitor Therapy
Nikoletta Lendvai (2015)
10.1200/JCO.2005.02.4091
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
E. Tan-chiu (2005)



This paper is referenced by
10.1002/ejhf.1569
Trends in modes of death in heart failure over the last two decades: less sudden death but cancer deaths on the rise
P. Moliner (2019)
10.1007/s10741-018-9731-y
Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology
P. Kostakou (2018)
Guidelines 2019 Focused Update of the Guidelines of the Taiwan Society of Cardiology for the Diagnosis and Treatment of Heart Failure
C. Wang (2019)
10.1016/j.jacc.2019.07.056
Cardiovascular Toxicities Associated With Ibrutinib.
J. Salem (2019)
10.1186/s40959-020-0057-2
Hospitalized cancer patients with acquired long QT syndrome-a matched case-control study
Yajuan Lin (2020)
10.1124/pr.116.013003
Patient and Disease–Specific Induced Pluripotent Stem Cells for Discovery of Personalized Cardiovascular Drugs and Therapeutics
David T. Paik (2020)
10.1007/s11886-020-1260-3
Second Hits in Dilated Cardiomyopathy
Peter Marstrand (2020)
10.1007/s10549-017-4628-3
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)
N. Pondé (2017)
10.3390/jcm9061702
Genetic Factors Involved in Cardiomyopathies and in Cancer
M. Sabater-Molina (2020)
10.1007/s11936-020-00809-x
State-of-the-art Review: Interventional Onco-Cardiology
Bala Pushparaji (2020)
10.1515/cclm-2020-0362
High-sensitivity cardiac troponin I and T methods for the early detection of myocardial injury in patients on chemotherapy.
A. Clerico (2020)
10.1097/FJC.0000000000000586
Possible Ameliorative Effect of Ivabradine on the Autonomic and Left Ventricular Dysfunction Induced by Doxorubicin in Male Rats
A. E. El-Naggar (2018)
10.1016/j.bulcan.2019.09.003
La myocardite : une toxicité rare mais grave sous immunothérapie
Pierre-Yves Courand (2019)
10.1007/s11936-019-0737-0
Cardiovascular Complications Associated with Mediastinal Radiation
Katherine Lee Chuy (2019)
10.1111/joim.12882
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension
S. Bringhen (2019)
10.1016/j.ctrv.2018.06.019
Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer.
J. Capdevila (2018)
10.3389/fphys.2018.00038
Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production
Gennaro Riccio (2018)
10.1182/blood-2017-03-725671
How I monitor long-term and late effects after blood or marrow transplantation.
S. Bhatia (2017)
10.1007/s11912-019-0785-3
Targeting Barriers of Systems of Care in a Growing Multi-disciplinary Field
Tolulope A. Agunbiade (2019)
10.1002/ejhf.1260
April 2019 at a glance: prediction of heart failure, left atrial function, cardio‐oncology
M. Metra (2019)
10.3390/cancers13010086
Monoclonal Antibody-Based Immunotherapy and Its Role in the Development of Cardiac Toxicity
M. Kumar (2020)
10.1007/s15004-017-5794-5
Zukünftige Entwicklungen in der Immunonkologie
Alexander Shimabukuro-Vornhagen (2017)
10.17709/2409-2231-2018-5-4-9
Организация программ реабилитации онкологических пациентов на основе междисциплинарного подхода
М. Ф. Баллюзек (2018)
10.1186/s40880-018-0343-7
The association between early-onset cardiac events caused by neoadjuvant or adjuvant chemotherapy in triple-negative breast cancer patients and some novel autophagy-related polymorphisms in their genomic DNA: a real-world study
Binliang Liu (2018)
Does it matter if it’s left or right? Echocardiographic image quality in patients after breast cancer surgery
Eivind Bjørkan Orstad (2018)
10.3390/ijerph17186814
Factors Affecting Onset and Persistence of Metabolic Syndrome in Korean Breast Cancer Survivors: A Prospective Study
Suyoun Maeng (2020)
10.1111/pace.13708
Acquired short QT syndrome in a cancer patient treated with Toad
Y. Huang (2019)
10.26355/eurrev_201804_14752
Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer.
M. A. Nicolazzi (2018)
Lösemi Hastalarında Kemoterapötiklerin Frontal QRS‐T Açısı Üzerine Etkisi
Özgür Kaplan (2020)
10.3389/fcvm.2017.00067
Cancer and Thrombotic Risk: The Platelet Paradigm
E. C. Lee (2017)
10.1016/j.hlc.2019.04.023
Echocardiography and Cardio-Oncology.
Tomoko Negishi (2019)
10.1016/j.amjcard.2019.07.015
Percutaneous Coronary Intervention and Outcomes in Patients With Lymphoma in the United States (Nationwide Inpatient Sample [NIS] Analysis).
J. A. Borovac (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar